Athersys Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Los beneficios de Athersys han disminuido a una tasa media anual de -12.5%, mientras que en la industria Biotechs los beneficios crecieron en un 12.7% anualmente. Los ingresos han ido disminuyendo a una tasa media de 44% al año.
Información clave
-12.5%
Tasa de crecimiento de los beneficios
3.0%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 17.0% |
| Tasa de crecimiento de los ingresos | -44.0% |
| Rentabilidad financiera | n/a |
| Margen neto | -46,883.8% |
| Última actualización de beneficios | 30 Sep 2023 |
Actualizaciones de resultados anteriores recientes
Recent updates
Athersys: Is Big Pharma Sleeping At The Wheel?
Oct 06Athersys extends exercise period of warrants in connection with recent offering
Sep 23Athersys announces 1-for-25 reverse stock split
Aug 25One Analyst's Revenue Estimates For Athersys, Inc. (NASDAQ:ATHX) Are Surging Higher
Aug 16
Athersys stock falls ~9% after reporting Q2 loss, fall in cash and cash equivalents
Aug 12Kasey Rosado named interim CFO of Athersys
Aug 04Athersys: Dead Man Walking
Jul 25Athersys: Focus On Stroke
May 04Athersys - Hero Or Zero Opportunity
Apr 18Athersys: Near-Term Progress In Stem Cell Phase 3 Trials Could Multiply Shares In 2022
Jan 20Here's Why Athersys (NASDAQ:ATHX) Must Use Its Cash Wisely
Dec 30Athersys: COVID-ARDS Is The Company's Most Important Target
Nov 25Athersys Shares Are Ready To Rumble Following Period Of Turmoil
Aug 30Athersys: Subgroup Analysis As A Masterstroke
Jul 29Here's Why We're Watching Athersys' (NASDAQ:ATHX) Cash Burn Situation
May 28Is Athersys (NASDAQ:ATHX) In A Good Position To Invest In Growth?
Feb 27Update On Athersys - Trying To Read Between The Lines
Feb 03Athersys: Risky Financial Position, But Promising Upside By FYE 2023
Feb 01Athersys: Stem Cell Opportunity For Risk Tolerant Investors
Nov 12Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Athersys. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -38 | 10 | 0 |
| 30 Jun 23 | 0 | -47 | 10 | 0 |
| 31 Mar 23 | 2 | -58 | 13 | 0 |
| 31 Dec 22 | 5 | -73 | 15 | 0 |
| 30 Sep 22 | 6 | -81 | 19 | 0 |
| 30 Jun 22 | 11 | -84 | 19 | -35 |
| 31 Mar 22 | 8 | -83 | 18 | 0 |
| 31 Dec 21 | 6 | -87 | 20 | 0 |
| 30 Sep 21 | 6 | -87 | 19 | 0 |
| 30 Jun 21 | 1 | -94 | 19 | 35 |
| 31 Mar 21 | 1 | -90 | 19 | 0 |
| 31 Dec 20 | 1 | -79 | 16 | 0 |
| 30 Sep 20 | 0 | -66 | 14 | 0 |
| 30 Jun 20 | 0 | -56 | 13 | 0 |
| 31 Mar 20 | 4 | -47 | 12 | 0 |
| 31 Dec 19 | 6 | -45 | 11 | 0 |
| 30 Sep 19 | 7 | -46 | 12 | 0 |
| 30 Jun 19 | 10 | -44 | 11 | 0 |
| 31 Mar 19 | 25 | -27 | 11 | 0 |
| 31 Dec 18 | 24 | -24 | 10 | 0 |
| 30 Sep 18 | 24 | -26 | 10 | 0 |
| 30 Jun 18 | 22 | -24 | 9 | 0 |
| 31 Mar 18 | 3 | -37 | 9 | 0 |
| 31 Dec 17 | 4 | -32 | 8 | 0 |
| 30 Sep 17 | 4 | -26 | 8 | 0 |
| 30 Jun 17 | 3 | -25 | 8 | 0 |
| 31 Mar 17 | 3 | -26 | 8 | 0 |
| 31 Dec 16 | 17 | -15 | 8 | 0 |
| 30 Sep 16 | 27 | -5 | 8 | 0 |
| 30 Jun 16 | 27 | -5 | 8 | 0 |
| 31 Mar 16 | 27 | 1 | 8 | 0 |
| 31 Dec 15 | 12 | -16 | 8 | 0 |
| 30 Sep 15 | 2 | -27 | 7 | 0 |
| 30 Jun 15 | 1 | -25 | 7 | 0 |
| 31 Mar 15 | 2 | -23 | 7 | 0 |
| 31 Dec 14 | 2 | -22 | 7 | 0 |
| 30 Sep 14 | 2 | -25 | 7 | 0 |
| 30 Jun 14 | 3 | -26 | 7 | 0 |
| 31 Mar 14 | 3 | -33 | 6 | 0 |
| 31 Dec 13 | 2 | -31 | 6 | 0 |
| 30 Sep 13 | 4 | -24 | 6 | 4 |
| 30 Jun 13 | 4 | -22 | 6 | 8 |
Ingresos de calidad: ATHX.Q is currently unprofitable.
Margen de beneficios creciente: ATHX.Q actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: ATHX.Q no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 12.5% al año.
Acelerando crecimiento: Unable to compare ATHX.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: ATHX.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Rentabilidad financiera
Alta ROE: ATHX.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.